EA201991697A1 - Сульфоксиминовые ингибиторы гликозидазы - Google Patents
Сульфоксиминовые ингибиторы гликозидазыInfo
- Publication number
- EA201991697A1 EA201991697A1 EA201991697A EA201991697A EA201991697A1 EA 201991697 A1 EA201991697 A1 EA 201991697A1 EA 201991697 A EA201991697 A EA 201991697A EA 201991697 A EA201991697 A EA 201991697A EA 201991697 A1 EA201991697 A1 EA 201991697A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sulfoxymine
- glycosidase inhibitors
- glycosidase
- inhibitors
- taupathies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Соединения формулы (I)где A, R, W, Q, n и m имеют значения, указанные в формуле изобретения, могут применяться, среди прочего, для лечения таупатий и болезни Альцгеймера.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621006636 | 2016-02-25 | ||
PCT/EP2017/054268 WO2017144633A1 (en) | 2016-02-25 | 2017-02-24 | Glycosidase inhibitors |
PCT/EP2017/071385 WO2018153508A2 (en) | 2017-02-24 | 2017-08-24 | Sulfoximine glycosidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991697A1 true EA201991697A1 (ru) | 2020-03-04 |
Family
ID=58159073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991697A EA201991697A1 (ru) | 2016-02-25 | 2017-08-24 | Сульфоксиминовые ингибиторы гликозидазы |
Country Status (12)
Country | Link |
---|---|
US (1) | US11612599B2 (ru) |
EP (1) | EP3419971B1 (ru) |
JP (2) | JP2019510006A (ru) |
KR (1) | KR20180132629A (ru) |
CN (2) | CN108884077A (ru) |
AU (1) | AU2017222958B2 (ru) |
CA (1) | CA3012560A1 (ru) |
EA (1) | EA201991697A1 (ru) |
MA (1) | MA43677A (ru) |
MX (1) | MX2018010192A (ru) |
WO (1) | WO2017144633A1 (ru) |
ZA (1) | ZA201905405B (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015308437C1 (en) | 2014-08-28 | 2020-11-05 | Asceneuron Sa | Glycosidase inhibitors |
MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
EA201891438A1 (ru) | 2016-02-25 | 2019-01-31 | Асенейрон С. А. | Кислотно-аддитивные соли производных пиперазина |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
AU2017378186A1 (en) | 2016-12-16 | 2019-06-13 | Janssen Pharmaceutica Nv | Monocyclic OGA inhibitor compounds |
SG11201907774VA (en) * | 2017-02-24 | 2019-09-27 | Asceneuron S A | Sulfoximine glycosidase inhibitors |
EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
US20210122763A1 (en) * | 2018-06-20 | 2021-04-29 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
EP3810595A1 (en) * | 2018-06-20 | 2021-04-28 | Janssen Pharmaceutica NV | Oga inhibitor compounds |
JP2021528404A (ja) * | 2018-06-21 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤化合物 |
MA52939A (fr) * | 2018-06-21 | 2021-04-28 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga |
TWI726329B (zh) | 2018-06-22 | 2021-05-01 | 美商美國禮來大藥廠 | 2,3-二氫呋喃并[2,3-b]吡啶化合物 |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
EP3841093B1 (en) | 2018-08-22 | 2023-06-21 | Asceneuron SA | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
TWI716107B (zh) * | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
CN111039946A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
IL293931A (en) | 2019-12-18 | 2022-08-01 | Janssen Pharmaceutica Nv | oga inhibitor compounds |
WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
JP2023507180A (ja) | 2019-12-18 | 2023-02-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤化合物 |
CN112028839B (zh) * | 2020-09-30 | 2022-04-12 | 中国海洋大学 | 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1311316A (fr) | 1961-04-12 | 1962-12-07 | Science Union Et Compagnie Soc | Nouveaux dérivés de la pipérazine et leurs préparations |
NL127996C (ru) | 1963-11-19 | |||
US3485757A (en) | 1964-11-23 | 1969-12-23 | Atomic Energy Commission | Thermoelectric composition comprising doped bismuth telluride,silicon and boron |
DE1595923A1 (de) | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung |
GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
US4600025A (en) | 1982-11-18 | 1986-07-15 | Grigg Ronald E | Smoking products comprising nicotine substitutes |
JPH07505648A (ja) | 1992-04-15 | 1995-06-22 | メルク シヤープ エンド ドーム リミテツド | アザサイクリック化合物 |
IL118768A (en) | 1995-07-12 | 2000-10-31 | Akzo Nobel Nv | Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation |
TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
CA2282390A1 (en) | 1997-04-17 | 1998-10-22 | Yukio Fujisawa | Thermogenic composition and benzazepine thermogenics |
WO1999021850A1 (en) | 1997-10-24 | 1999-05-06 | Neurogen Corporation | 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d4 receptor subtype ligands |
CA2448080A1 (en) * | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US6921821B2 (en) | 2002-06-12 | 2005-07-26 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
DK1519939T5 (da) | 2002-07-05 | 2011-01-24 | Targacept Inc | N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf |
AU2003268512A1 (en) | 2002-09-09 | 2004-03-29 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
EP1626958B1 (en) | 2003-04-18 | 2012-06-27 | Eli Lilly And Company | (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists |
EP1630162A4 (en) | 2003-05-21 | 2010-06-09 | Banyu Pharma Co Ltd | 2-aminoquinoline derivative |
WO2005066145A1 (en) | 2004-01-06 | 2005-07-21 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
US7253168B2 (en) | 2004-04-07 | 2007-08-07 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
HU227119B1 (en) | 2004-07-29 | 2010-07-28 | Richter Gedeon Nyrt | Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them |
HUP0401522A2 (en) | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation |
JP5154954B2 (ja) | 2005-03-01 | 2013-02-27 | サイモン フレイザー ユニバーシティ | 選択的なグリコシダーゼインヒビター、インヒビターを作製する方法、およびインヒビターの使用 |
EP1705177A1 (en) * | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
TW200724140A (en) | 2005-05-27 | 2007-07-01 | Eisai Co Ltd | Hydantoin compounds |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
BRPI0711040A2 (pt) | 2006-03-31 | 2011-08-23 | Astrazeneca Ab | uso de um composto, método para o tratamento ou prevenção de distúrbios, composto, e, composição farmacêutica |
CN101448827A (zh) | 2006-05-22 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 吲哚衍生物 |
US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
JP5380293B2 (ja) | 2006-08-31 | 2014-01-08 | サイモン・フレーザー・ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
US20100022517A1 (en) | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
WO2009011904A1 (en) | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
ES2448870T3 (es) | 2007-10-26 | 2014-03-17 | Janssen Pharmaceutica, N.V. | Derivados de quinolina como inhibidores de PARP |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
CA2719784A1 (en) | 2008-04-17 | 2009-10-22 | Pfizer Inc. | Ether benzylidene piperidine 5-membered aryl carboxamide compounds |
WO2009127948A1 (en) | 2008-04-17 | 2009-10-22 | Pfizer Inc. | 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
WO2010021381A1 (ja) | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
WO2010022517A1 (en) | 2008-08-29 | 2010-03-04 | Saint Mary's University | Use of gluconacetobacter with reduced use of nitrogen fertilizer to improve beet crop production |
KR101667063B1 (ko) | 2008-09-02 | 2016-10-17 | 닛산 가가쿠 고교 가부시키 가이샤 | 오르토 치환 할로알킬술폰아닐리드 유도체 및 제초제 |
TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
WO2010101949A1 (en) | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
US20100240720A1 (en) | 2009-03-20 | 2010-09-23 | Burnham Institute For Medical Research | Allosteric jnk inhibitors |
US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
JP2010270034A (ja) | 2009-05-20 | 2010-12-02 | Sumitomo Chemical Co Ltd | アミド化合物並びにその植物病害防除用途 |
WO2010151318A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2012037298A1 (en) | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
EP2638052B1 (en) | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
PT2655388T (pt) | 2010-12-23 | 2016-09-06 | Merck Sharp & Dohme | Inibidores de glicosidase seletivos e as suas utilizações |
GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
TW201300358A (zh) | 2011-03-14 | 2013-01-01 | 大正製藥股份有限公司 | 含氮縮合雜環化合物 |
JP5893738B2 (ja) | 2011-08-25 | 2016-03-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール |
WO2013066729A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
EP2882733B1 (en) | 2012-08-08 | 2017-04-26 | Novartis Tiergesundheit AG | Substituted azines as pesticides |
WO2014032187A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014159234A1 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Glycosidase inhibitors |
CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
MA39092B1 (fr) | 2013-12-05 | 2018-09-28 | Pfizer | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides |
EP2913330A1 (en) | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
SI3597649T1 (sl) | 2014-04-23 | 2022-04-29 | Dart Neuroscience Llc | Sestavki, ki vsebujejo substituirane (1,2,4)triazolo(1,5-a)pirimidin-7-ilne spojine, kot zaviralci pde2 |
AR101197A1 (es) * | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas |
AU2015308437C1 (en) * | 2014-08-28 | 2020-11-05 | Asceneuron Sa | Glycosidase inhibitors |
CA2963951C (en) * | 2014-10-08 | 2023-02-28 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
TR201908151T4 (tr) * | 2014-10-08 | 2019-06-21 | Ucb Biopharma Sprl | İzoindolin türevleri. |
PT3221306T (pt) * | 2014-11-20 | 2020-02-19 | Merck Patent Gmbh | Compostos de heteroarilo como inibidores de irak e utilização dos mesmos |
TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
EP3316969B1 (en) | 2015-07-02 | 2022-03-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
US10947239B2 (en) | 2015-11-02 | 2021-03-16 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
ES2915550T3 (es) * | 2015-11-06 | 2022-06-23 | Incyte Corp | Compuestos heterocíclicos como inhibidores de PI3K-gamma |
WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
WO2017087863A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
EP3380471B8 (en) | 2015-11-25 | 2022-01-19 | Lieber Institute Inc. DBA Lieber Institute For Brain Development | Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders |
EP3389658B1 (en) | 2015-12-18 | 2020-11-25 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
EA201891438A1 (ru) | 2016-02-25 | 2019-01-31 | Асенейрон С. А. | Кислотно-аддитивные соли производных пиперазина |
CN108884081B (zh) | 2016-02-25 | 2022-11-01 | 阿森纽荣股份公司 | 分离哌嗪衍生物的对映体的方法 |
MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
AU2017378186A1 (en) | 2016-12-16 | 2019-06-13 | Janssen Pharmaceutica Nv | Monocyclic OGA inhibitor compounds |
US20190359609A1 (en) | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
AR110747A1 (es) | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
JP2020506940A (ja) | 2017-02-06 | 2020-03-05 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害化合物 |
SG11201907774VA (en) | 2017-02-24 | 2019-09-27 | Asceneuron S A | Sulfoximine glycosidase inhibitors |
JP2020509004A (ja) | 2017-02-27 | 2020-03-26 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている[1,2,4]−トリアゾロ[1,5−a]−ピリミジニル誘導体 |
TWI669302B (zh) | 2017-05-25 | 2019-08-21 | 美商美國禮來大藥廠 | 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物 |
EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
EP3841093B1 (en) | 2018-08-22 | 2023-06-21 | Asceneuron SA | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
US20210213005A1 (en) | 2018-08-22 | 2021-07-15 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
US20220143042A1 (en) | 2019-02-22 | 2022-05-12 | Asceneuron Sa | Fused glycosidase inhibitors |
-
2017
- 2017-02-24 MX MX2018010192A patent/MX2018010192A/es unknown
- 2017-02-24 CN CN201780011547.3A patent/CN108884077A/zh active Pending
- 2017-02-24 JP JP2018544466A patent/JP2019510006A/ja not_active Withdrawn
- 2017-02-24 EP EP17707008.3A patent/EP3419971B1/en active Active
- 2017-02-24 MA MA043677A patent/MA43677A/fr unknown
- 2017-02-24 KR KR1020187025792A patent/KR20180132629A/ko unknown
- 2017-02-24 AU AU2017222958A patent/AU2017222958B2/en not_active Revoked
- 2017-02-24 CA CA3012560A patent/CA3012560A1/en not_active Withdrawn
- 2017-02-24 US US16/078,159 patent/US11612599B2/en active Active
- 2017-02-24 WO PCT/EP2017/054268 patent/WO2017144633A1/en active Application Filing
- 2017-08-24 EA EA201991697A patent/EA201991697A1/ru unknown
- 2017-08-24 CN CN201780089984.7A patent/CN110770226B/zh active Active
- 2017-08-24 JP JP2019545961A patent/JP7082446B2/ja active Active
-
2019
- 2019-08-15 ZA ZA2019/05405A patent/ZA201905405B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019510006A (ja) | 2019-04-11 |
EP3419971B1 (en) | 2022-04-20 |
JP7082446B2 (ja) | 2022-06-08 |
KR20180132629A (ko) | 2018-12-12 |
US11612599B2 (en) | 2023-03-28 |
CN110770226B (zh) | 2023-11-10 |
AU2017222958A1 (en) | 2018-08-02 |
CA3012560A1 (en) | 2017-08-31 |
MA43677A (fr) | 2018-11-28 |
EP3419971A1 (en) | 2019-01-02 |
MX2018010192A (es) | 2019-01-31 |
AU2017222958B2 (en) | 2019-07-18 |
JP2020509003A (ja) | 2020-03-26 |
CN108884077A (zh) | 2018-11-23 |
US20210186958A1 (en) | 2021-06-24 |
CN110770226A (zh) | 2020-02-07 |
ZA201905405B (en) | 2021-08-25 |
WO2017144633A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991697A1 (ru) | Сульфоксиминовые ингибиторы гликозидазы | |
EA201790271A1 (ru) | Ингибиторы гликозидазы | |
MX2018010191A (es) | Inhibidores de glucosidasa. | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
EA201790317A1 (ru) | Ингибиторы smyd | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
EA201790376A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
EA201692513A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201990044A1 (ru) | Гетероциклические соединения в качестве антибактериальных средств | |
EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
MX2018008815A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2019010085A (es) | Inhibidores de la glicosidasa de sulfoximina. | |
GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
EA201790327A1 (ru) | Соединения замещенного пиперидина | |
EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
EA201990400A1 (ru) | Соединения и композиции и их применение |